Artículos por tema "KRAS-targeted therapy"

1. KRAS Inhibitors — The "Undruggable Target"? A Thing of the Past
   posted this at 9 jun 2025

   2
   KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is a key member of the RAS family. Mutations in KRAS are among the most common oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. It is estimated that KRAS mutations ...
2. Traditional Chinese Medicine Molecule RA-V: A Potential Synergistic Factor in KRAS G12C Inhibition
   posted this at 9 jun 2025

   2
   The KRAS G12C mutation is one of the common driver mutations in malignant tumors such as colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Recently approved KRAS G12C inhibitors like Adagrasib (MRTX849) and Sotorasib have provided unprecedented therapeutic options for patients.